Table 2.
Clinicopathological and treatment characteristics of the included patients in this study
| Parameter | Total group | SLNB+ group | P * |
|---|---|---|---|
| Screening detected | 364 | 11 | 0.350 |
| Symptomatic (palpable) | 96 | 5 | |
| Necrosis present | 691 | 30 | <0.001 |
| Necrosis absent | 1127 | 16 | |
| Microcalcification present | 226 | 13 | 0.309 |
| Microcalcification absent | 126 | 15 | |
| Grade 1 | 325 | 7 | 0.969† |
| Grade 2 | 1039 | 24 | |
| Grade 3 | 1614 | 35 | |
| Grade 1/2 | 1727 | 31 | 0.447 |
| Grade 3 | 1614 | 35 | |
| ER+ | 825 | 9 | 0.299 |
| ER− | 381 | 7 | |
| PgR+ | 802 | 9 | 0.386 |
| PgR− | 403 | 7 | |
| HER2+ | 479 | 4 | 0.270 |
| HER2− | 765 | 12 | |
| Ki67 < 20% | 324 | 9 | 0.096 |
| Ki67 > 20% | 446 | 5 | |
| BCS | 1205 | 12 | 0.016 |
| Mastectomy | 2514 | 9 |
SLNB+, metastatic lymph nodes on sentinel lymph node biopsy; ER, oestrogen receptor; PgR, progesterone receptor; HER2, human epidermal growth factor receptor-2; BCS, breast conservation surgery. *P values from Fisher’s exact test unless otherwise stated; †χ2 test.